Reinfecções pelo SARS-CoV-2: fato ou fake? Implicações para a resposta vacinal
Reinfection with SARS-CoV-2: fact or fake? Implications for vaccine response
Dewton de Moraes Vasconcelos; Lorena de Castro Diniz; Ekaterini Goudouris; Ana Karolina Barreto Berselli Marinho; Carolina Prando; Norma de Paula Motta Rubini; Emanuel Sávio Cavalcanti Sarinho; Pedro Giavina-Bianchi
Resumo
Há evidências atuais de que a reinfecção pelo SARS-CoV-2 é uma realidade, mas na grande maioria das situações não houve investigação que permitisse sua perfeita caracterização, sendo confirmados poucos casos. Em situações de real reinfecção, esta ocorreu, em sua grande maioria, por variantes do vírus, com diversas mutações, usualmente na proteína da espícula viral, em profissionais de saúde altamente expostos, ou em portadores de imunodeficiências, tanto primárias quanto secundárias. Ressaltamos que as vacinas podem ser modificadas com relativa facilidade, mas a capacidade de fabricação e de distribuição pelo mundo será capaz de acompanhar a demanda por vacinação em massa de forma eficiente? Neste manuscrito, a comissão de estudo da COVID-19 da ASBAI analisa criticamente o conhecimento atual sobre a reinfecção pelo SARS-CoV-2.
Palavras-chave
Abstract
There is current evidence that reinfection with SARS-CoV-2 is a reality, but there is also a lack of investigation that would allow its perfect characterization, and few cases have been confirmed. Real reinfections occurred mostly with variants of the virus, with several mutations, usually in the viral spike protein, in highly exposed health professionals or in patients with immunodeficiencies, both primary and secondary. We emphasize that vaccines can be modified relatively easily, but will the manufacturing and distribution capacity around the world be able to keep up with the demand for mass vaccination efficiently? The ASBAI COVID-19 study commission critically analyzes in this manuscript the current knowledge about SARS-CoV-2 reinfection.
Keywords
References
1. Kim DS, Rowland-Jones S, Gea-Mallorquı E. Will SARS-CoV-2 infection elicit long lasting protective or sterilising immunity? Implications for vaccine strategies (2020). Front Immunol. 2020;11:571481. doi: 10.3389/fimmu.2020.571481.
2. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. MedRX. 2020 [pre-print]. doi: 10.1101/2020.12.21.20248640.
3. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and severity of novel SARSCoV-2 Variant of Concern 202012/01 in England. MedRX. 2020 [pre-print]. doi: 10.1101/2020.12.24.20248822.
4. Andreano E, Piccini G, Licastro D, Casalino L, Johnson NV, Paciello I, et al. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. BioRX. 2020 [pre-print]. doi: 10.1101/2020.12.28.424451.
5. Xie X, Zou J, Fontes-Garfias CR, Xia H, Swanson KA, Cutler M, et al. Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. BioRX. 2021 [pre-print]. doi: 10.1101/01.07.425740.
6. Victor Okhuese A. Estimation of the probability of reinfection with COVID-19 by the susceptible-exposed-infectious-removedundetectable-susceptible model. JMIR Public Health Surveill. 2020;6(2):e19097. doi: 10.2196/19097.
7. Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, Bloom JD, et al. Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies. BioRX. 2021 [pre-print]. doi: 10.1101/2020.12.31.425021.
8. Madan M, Kunal S. COVID-19 reinfection or relapse: an intriguing dilemma. Clin Rheumatol. 2020;39(11):3189. doi: 10.1007/s10067-020-05427-3.
9. Falahi S, Kenarkoohi A. COVID-19 reinfection: prolonged shedding or true reinfection? New Microbes New Infect. 2020;38:100812. doi: 10.1016/j.nmni.2020.100812.
10. Cento V, Colagrossi L, Nava A, Lamberti A, Senatore S, et al. Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients. J Infect. 2020;81(3):e90‑e92. doi: 10.1016/j.jinf.2020.06.024.
11. Mattiuzzi C, Henry BM, Sanchis-Gomar F, Lippi G. SARS-CoV-2 recurrent RNA positivity after recovering from coronavirus disease 2019 (COVID-19): a meta-analysis. Acta Biomed. 2020;91(3):e2020014. doi: 10.23750/abm.v91i3.10303.
12. Kang H, Wang Y, Tong Z, Liu X. Retest positive for SARS-CoV-2 RNA of “recovered” patients with COVID-19: Persistence, sampling issues, or re-infection? J Med Virol. 2020;92:2263‑65. doi: 10.1002/ jmv.26114.
13. Cohen JI, Burbelo PD. Reinfection with SARS-CoV-2: Implications for Vaccines. Clinical Infectious Diseases. 2021 [pre-print]. doi: 10.1093/cid/ciaa1866.
Submitted date:
02/19/2021
Accepted date:
02/26/2021
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email